Literature DB >> 25406193

Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.

Inmaculada Spiteri1, Andrea Sottoriva1,2, Sara Gm Piccirillo3, Anestis Touloumis1,4, Suzan Ber3, Stephen J Price5, Richard Heywood3, Nicola-Jane Francis6, Karen D Howarth7, Vincent P Collins8, Ashok R Venkitaraman6, Christina Curtis2, John C Marioni4, Simon Tavaré1, Colin Watts3,5.   

Abstract

Glioblastoma, the most common and aggressive adult brain tumor, is characterized by extreme phenotypic diversity and treatment failure. Through fluorescence-guided resection, we identified fluorescent tissue in the sub-ependymal zone (SEZ) of patients with glioblastoma. Histologic analysis and genomic characterization revealed that the SEZ harbors malignant cells with tumor-initiating capacity, analogous to cells isolated from the fluorescent tumor mass (T). We observed resistance to supramaximal chemotherapy doses along with differential patterns of drug response between T and SEZ in the same tumor. Our results reveal novel insights into glioblastoma growth dynamics, with implications for understanding and limiting treatment resistance. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 25406193      PMCID: PMC4286248          DOI: 10.1158/0008-5472.CAN-13-3131

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

Review 1.  Counting divisions in a human somatic cell tree: how, what and why?

Authors:  Darryl Shibata; Simon Tavaré
Journal:  Cell Cycle       Date:  2006-03-15       Impact factor: 4.534

Review 2.  TM4 microarray software suite.

Authors:  Alexander I Saeed; Nirmal K Bhagabati; John C Braisted; Wei Liang; Vasily Sharov; Eleanor A Howe; Jianwei Li; Mathangi Thiagarajan; Joseph A White; John Quackenbush
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

3.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

4.  Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.

Authors:  Yuan Zhu; Frantz Guignard; Dawen Zhao; Li Liu; Dennis K Burns; Ralph P Mason; Albee Messing; Luis F Parada
Journal:  Cancer Cell       Date:  2005-08       Impact factor: 31.743

5.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

Authors:  Jeongwu Lee; Svetlana Kotliarova; Yuri Kotliarov; Aiguo Li; Qin Su; Nicholas M Donin; Sandra Pastorino; Benjamin W Purow; Neil Christopher; Wei Zhang; John K Park; Howard A Fine
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

6.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.

Authors:  S G M Piccirillo; B A Reynolds; N Zanetti; G Lamorte; E Binda; G Broggi; H Brem; A Olivi; F Dimeco; A L Vescovi
Journal:  Nature       Date:  2006-12-07       Impact factor: 49.962

7.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model.

Authors:  Sheila Alcantara Llaguno; Jian Chen; Chang-Hyuk Kwon; Erica L Jackson; Yanjiao Li; Dennis K Burns; Arturo Alvarez-Buylla; Luis F Parada
Journal:  Cancer Cell       Date:  2009-01-06       Impact factor: 31.743

9.  Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype.

Authors:  Daniel A Lim; Soonmee Cha; Mary C Mayo; Mei-Hsiu Chen; Evren Keles; Scott VandenBerg; Mitchel S Berger
Journal:  Neuro Oncol       Date:  2007-07-10       Impact factor: 12.300

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  27 in total

1.  Reactive species balance via GTP cyclohydrolase I regulates glioblastoma growth and tumor initiating cell maintenance.

Authors:  Anh Nhat Tran; Kiera Walker; David G Harrison; Wei Chen; James Mobley; Lauren Hocevar; James R Hackney; Randee S Sedaka; Jennifer S Pollock; Matthew S Goldberg; Dolores Hambardzumyan; Sara J Cooper; Yancey Gillespie; Anita B Hjelmeland
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

Review 2.  Space Invaders: Brain Tumor Exploitation of the Stem Cell Niche.

Authors:  Justine Sinnaeve; Bret C Mobley; Rebecca A Ihrie
Journal:  Am J Pathol       Date:  2017-10-10       Impact factor: 4.307

Review 3.  Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.

Authors:  Subramanian Venkatesan; Martine L M Lamfers; Clemens M F Dirven; Sieger Leenstra
Journal:  CNS Oncol       Date:  2016-03-17

4.  CD15 Expression Does Not Identify a Phenotypically or Genetically Distinct Glioblastoma Population.

Authors:  Emma Kenney-Herbert; Talal Al-Mayhani; Sara G M Piccirillo; Joanna Fowler; Inmaculada Spiteri; Philip Jones; Colin Watts
Journal:  Stem Cells Transl Med       Date:  2015-05-27       Impact factor: 6.940

5.  EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.

Authors:  Eskil Eskilsson; Gro V Rosland; Krishna M Talasila; Stian Knappskog; Olivier Keunen; Andrea Sottoriva; Sarah Foerster; Gergely Solecki; Torfinn Taxt; Radovan Jirik; Sabrina Fritah; Patrick N Harter; Kristjan Välk; Jubayer Al Hossain; Justin V Joseph; Roza Jahedi; Halala S Saed; Sara G Piccirillo; Inma Spiteri; Lina Leiss; Philipp Euskirchen; Grazia Graziani; Thomas Daubon; Morten Lund-Johansen; Per Øyvind Enger; Frank Winkler; Christoph A Ritter; Simone P Niclou; Colin Watts; Rolf Bjerkvig; Hrvoje Miletic
Journal:  Neuro Oncol       Date:  2016-06-10       Impact factor: 12.300

6.  CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone.

Authors:  Nicolas Goffart; Arnaud Lombard; François Lallemand; Jérôme Kroonen; Jessica Nassen; Emmanuel Di Valentin; Sharon Berendsen; Matthias Dedobbeleer; Estelle Willems; Pierre Robe; Vincent Bours; Didier Martin; Philippe Martinive; Pierre Maquet; Bernard Rogister
Journal:  Neuro Oncol       Date:  2016-07-01       Impact factor: 12.300

7.  In Vivo Selection of a Computationally Designed SCHEMA AAV Library Yields a Novel Variant for Infection of Adult Neural Stem Cells in the SVZ.

Authors:  David S Ojala; Sabrina Sun; Jorge L Santiago-Ortiz; Mikhail G Shapiro; Philip A Romero; David V Schaffer
Journal:  Mol Ther       Date:  2017-09-08       Impact factor: 11.454

Review 8.  Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has multimodal imaging come?

Authors:  Natalie R Boonzaier; Sara G M Piccirillo; Colin Watts; Stephen J Price
Journal:  CNS Oncol       Date:  2015-10-26

9.  The inverse paradigm and the ancestral cell of IDH-wildtype glioblastoma.

Authors:  Enrico Brognaro
Journal:  Clin Transl Oncol       Date:  2021-06-21       Impact factor: 3.405

Review 10.  Fluorescence-Guided Surgery for High-Grade Gliomas: State of the Art and New Perspectives.

Authors:  Giuseppe Palmieri; Fabio Cofano; Luca Francesco Salvati; Matteo Monticelli; Pietro Zeppa; Giuseppe Di Perna; Antonio Melcarne; Roberto Altieri; Giuseppe La Rocca; Giovanni Sabatino; Giuseppe Maria Barbagallo; Fulvio Tartara; Francesco Zenga; Diego Garbossa
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.